# A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease

Study · id `cardio:ct-nct07848880` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07848880](<https://clinicaltrials.gov/study/NCT07848880>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07848880

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 315 participants.

## Technical summary

Registry record NCT07848880. Randomized; quadruple masking; primary purpose treatment. Start 2026-10 (anticipated); primary completion 2028-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 315 participants (planned count; ClinicalTrials.gov record NCT07848880, source copy `cardio:ctgov-nct07848880-2026-09-30`, retrieved 2026-10-31)
- Planned start: 2026-10 (anticipated) (ClinicalTrials.gov record NCT07848880, source copy `cardio:ctgov-nct07848880-2026-09-30`, retrieved 2026-10-31)
- Primary completion: 2028-04 (anticipated) (ClinicalTrials.gov record NCT07848880, source copy `cardio:ctgov-nct07848880-2026-09-30`, retrieved 2026-10-31)
- Completion: 2029-03 (anticipated) (ClinicalTrials.gov record NCT07848880, source copy `cardio:ctgov-nct07848880-2026-09-30`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07848880, source copy `cardio:ctgov-nct07848880-2026-09-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07848880-2026-09-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease
- Condition: Hypertriglyceridemia
- Intervention (Drug): DR10624 Injection
- Intervention (Drug): Placebo
- Lead sponsor: Zhejiang Doer Biologics Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry lists this organization as the lead sponsor: Zhejiang Doer Biologics Co., Ltd. (`cardio:org-zhejiang-doer-biologics-co-ltd`)

## Provenance

Content hash: 4687a7090b6dd84d5f596870977b508e4a3979d45c215ba5cd8fc904e849070e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
